Novartis Consumer Health advises the consumers who have purchased these recalled products to discontinue the use and return them to Novartis Consumer Health for a full refund. These actions have been communicated to the US Food and Drug Administration (FDA) as well as the FDA. More info will be found in fda.gov.
If you have Bufferin products with expiry dates of December 20, 2013 or earlier, you need to discontinue the usage. Here's the product: Bufferin Extra Strength Tablets, Bufferin Low Dose Tablets, and Bufferin Regular Strength Tablets
This is a voluntary recall by Novartis Consumer Health for the following products: Excedrin, NoDoz, Bufferin and Gas-X Prevention in the United States only.
These products may contain stray tablets from other Novartis products or contain broken or chipped tablets. They are not aware of any adverse events reported with the issues leading to the recall. But, this comprehensive recall is in the best interest of consumers.
You can contact Novartis Consumer Relationship Center at 1-888-477-2403 Monday-Friday from 9 a.m. to 8 p.m. Eastern Time for information on how to return the affected products and receive reimbursement.
Select bottle sizes of Excedrin and NoDoz products with expiry dates of December 20, 2014 or earlier as well as Gas-X Prevention products with expiry dates of December 20, 2013 or earlier, in the United States have been recalled.
I am using Excedrin for my migraine relief. If you have these in your medicine cabinet, discontinue the usage:
Excedrin Extra Strength Caplets
Excedrin Extra Strength Express Gel Caplets
Excedrin Extra Strength Gel Caplets
Excedrin Extra Strength Tablets
Excedrin Back & Body Caplets
Excedrin Sinus Headache Caplets
Excedrin Migraine Caplets
Excedrin Migraine Gel Tablets
Excedrin Migraine Tablets
Excedrin Menstrual Complete Express Gel Caplets
Excedrin PM Caplets
Excedrin PM Express Gel Caplets
Excedrin PM Tablets
Excedrin Tension Headache Caplets
Excedrin Tension Headache Express Gel Caplets
Excedrin Tension Headache Gel Tablets
source: novartis.com/newsroom/media-releases/index.shtml